University of Indonesia
🇮🇩Indonesia
- Country
- 🇮🇩Indonesia
- Ownership
- Private
- Established
- 1849-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.ui.ac.id/en
Clinical Trials
414
Active:11
Completed:276
Trial Phases
6 Phases
Early Phase 1:6
Phase 1:19
Phase 2:28
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (353 trials with phase data)• Click on a phase to view related trials
Not Applicable
245 (69.4%)Phase 4
30 (8.5%)Phase 2
28 (7.9%)Phase 3
25 (7.1%)Phase 1
19 (5.4%)Early Phase 1
6 (1.7%)Development of a Dietary Intervention Model Based on Genetic Data as an Implementation of a Healthy Lifestyle in the Management of Systemic Lupus Erythematosus Patients
Not Applicable
Not yet recruiting
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 100
- Registration Number
- NCT07183007
- Locations
- 🇮🇩
Cipto Mangunkusumo Hospital, Jakarta Pusat, Jakarta Special Capital Region, Indonesia
Dietary Patterns, Inflammation, Zinc Status, and Body Composition in Multi-Ethnic Women of Reproductive Age in Jakarta
Recruiting
- Conditions
- Body CompositionDietary AnalysisZinc StatusBlood PressureTNF Alpha
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 188
- Registration Number
- NCT07170904
- Locations
- 🇮🇩
Human Nutrition Research Center (HNRC) Laboratory, IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia
Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy
Not Applicable
Completed
- Conditions
- Proliferative VitreoretinopathyRhegmatogenous Retinal Detachment
- Interventions
- Drug: Control (placebo) group
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 61
- Registration Number
- NCT07162818
- Locations
- 🇮🇩
Department of Ophthalmology, Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta, Jakarta Pusat, Indonesia
Mesenchymal Stromal/Stem Cells-Derived Exosomes (MSC-Exos) Therapy for Type 2 Diabetes Mellitus Patients
Not Applicable
Not yet recruiting
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Biological: Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS + 1 vial Exo-HUVEC) TherapyBiological: Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS ) Therapy
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 50
- Registration Number
- NCT07144241
- Locations
- 🇮🇩
UNIMUS Hospital, Semarang, Central Java, Indonesia
ED50 of Dexmedetomidine as an Adjuvant to 0.5% Hyperbaric Bupivacaine 12.5 mg for Spinal Anesthesia in Hip and Knee Surgery: An Up-and-Down Method Approach
Not Applicable
Completed
- Conditions
- Knee SurgeryPelvic SurgerySpinal Aneshtesia
- Interventions
- Drug: Dexmedetomidine 3 mcgDrug: Dexmedetomidine 4 mcgDrug: Dexmedetomidine 5 mcgDrug: Dexmedetomidine 6 mcgDrug: Bupivacain hyperbaric 0.5% 12.5 mg
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 40
- Registration Number
- NCT07144215
- Locations
- 🇮🇩
RSUPN Cipto Mangunkusumo, Jakarta Pusat, Jakarta Special Capital Region, Indonesia
- Prev
- 1
- 2
- 3
- 4
- 5
- 83
- Next
News
No news found